GlaxoSmithKline Tells Court It Aims to Seek Enhanced Damages in $235M Patent Case
GlaxoSmithKline told a Delaware federal judge on Monday that it will seek enhanced damages on a $235 million verdict against Teva Pharmaceutical for willfully infringing a patent for its hypertension drug Coreg.
This premium content is reserved for Delaware Business Court Insider subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now